Coronary Artery Stenosis Clinical Trial
Official title:
Comparing the Safety and Efficacy of Cordimax and Xience V Drug-eluting Stents, for the Treatment of Coronary Heart Disease (CHD) in the Clinical Research of Real World
Study purpose: This study is a prospective, randomized, controlled multicenter clinical
research, which is to assess the effect of Cordimax and Xience V drug-eluting stents as they
dealing with all kinds of complex lesions in the real world.
Study group Experimental group: Cordimax® Rapamycin Eluting Coronary Stent System Control
group: XIENCE V® Everolimus Eluting Coronary Stent System
The purpose of the post market clinical trial is to evaluate the safety and efficacy of the
Cordimax Rapamycin Eluting Coronary Stent System (RECS). The Cordimax will be compared to an
active control group represented by the FDA approved commercially available Abbott Vascular
XIENCE V® EECS Everolimus Eluting Coronary Stent System.
The post market clinical trial consists of a randomized clinical trial (RCT) in China which
will enroll approximately 3660 subjects (2:1 randomization Cordimax® RECS : XIENCE V® EECS)
with a maximum of two de novo native coronary artery lesion treatment within vessel sizes >=
2.5 mm and <= 4 mm.
All subjects in the RCT will be screened per the protocol required inclusion/exclusion
criteria. The data collected will be compared to data from the subjects enrolled into the
XIENCE V® arm of US RCT.
All subjects will have clinical follow-up at 30, 60, 90days, and 1, 2, 3, 4, and 5 years so
as to collect the needed data for the subsequent analysis.(Data collecting at 1st year will
be conducted in the clinic in order to get the 12 lead ecg result once after out of the
hospital) .
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05133843 -
Complete Functional Assessment of Intermediate Coronary Artery Stenosis Before and After Transcatheter Aortic Valve Implantation (TAVI) in Patients With Severe Symptomatic Aortic Valve Stenosis
|
N/A | |
| Completed |
NCT01205776 -
EXCEL Clinical Trial
|
N/A | |
| Completed |
NCT01332591 -
Multivessel Disease Diagnosed at the Time of PPCI for STEMI: Complete Revascularization Versus Conservative Strategy.
|
N/A | |
| Completed |
NCT01182428 -
XIENCE V: SPIRIT WOMEN Sub-study
|
Phase 4 | |
| Completed |
NCT00739466 -
Biorest Liposomal Alendronate With Stenting sTudy (BLAST)
|
Phase 2 | |
| Completed |
NCT01310309 -
EXecutive Registry: Evaluating XIENCE V® in a Multi Vessel Disease
|
Phase 4 | |
| Completed |
NCT00531011 -
EXecutive RCT: Evaluating XIENCE V® in a Multi Vessel Disease
|
Phase 4 | |
| Not yet recruiting |
NCT06052670 -
Functional Diagnostic Accuracy of Ultrasonic Flow Ratio in Assessment of Coronary Artery Lesions
|
||
| Completed |
NCT05509296 -
Compare the Effectiveness and Safety of Two Different Kinds of Cutting Balloon in Coronary Artery Disease
|
N/A | |
| Not yet recruiting |
NCT05393882 -
Impact of Cholesterol Level on Long-term Coronary Bypass Graft Patency
|
||
| Recruiting |
NCT06397820 -
Relation Between AI-QCA and Cardiac PET
|
||
| Active, not recruiting |
NCT01960504 -
First in Man Study of the DREAMS 2nd Generation Drug Eluting Absorbable Metal Scaffold (BIOSOLVE-II)
|
N/A | |
| Completed |
NCT01721096 -
XIENCE PRIME Japan Post-Marketing Surveillance (PMS)
|
||
| Active, not recruiting |
NCT01342822 -
Trial to Assess the Everolimus-Eluting Coronary Stent System (PROMUS Element) for Coronary Revascularization
|
Phase 4 | |
| Completed |
NCT01205789 -
EXCEL Clinical Trial (Universal Registry)
|
N/A | |
| Recruiting |
NCT05532605 -
Effects of Mindfulness Based Therapy on Illness and Depression in Cardiac Rehab Phase-i
|
N/A | |
| Completed |
NCT02066623 -
Observational Study to Evaluate Short and Long-term Safety of the ABSORB Scaffold
|
||
| Not yet recruiting |
NCT02946320 -
Optimal Predilatation Technique for BVS Implantation
|
Phase 3 | |
| Terminated |
NCT01136915 -
Kidney Damage In Patients With Severe Fall In eGFR
|
Phase 4 | |
| Completed |
NCT01136876 -
Kidney Damage in Patients With Moderate Fall in eGFR
|
Phase 4 |